Sub-Licensees
Shasun Pharma Solutions
Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].
On 25 February 2013, the MPP signed a sublicensing agreement with active pharmaceutical ingredient manufacturer Shasun Pharma Solutions.
Laurus Labs
Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].
On 26 September 2012, the MPP signed a sublicensing agreement with active pharmaceutical ingredient manufacturer Laurus Labs.
Hetero Labs
Sub-licences covering: emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].
In July 2012, the MPP signed a sublicensing agreement with leading generic ARV manufacturer Hetero. Hetero, like Aurobindo and Emcure, chose to take advantage of a key provision negotiated by the Pool so it can sell tenofovir to a larger number of countries and without paying royalties.
Emcure Pharmaceuticals Limited
Sub-licences covering: emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].
In January 2012, the MPP signed a sublicensing agreement with key generics manufacturer Emcure. Emcure, like Aurobindo, chose to take advantage of a key provision negotiated by the Pool so it can sell tenofovir to a larger number of countries and without paying royalties.
- 2 February 2012 Press Release
- Fully executed sublicence agreement, with TDF termination notice [pdf]
Aurobindo Pharma Limited
Sub-licences covering: emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].
In October 2011, the MPP signed a sublicensing agreement with key generics manufacturer Aurobindo. Aurobindo chose to take advantage of a key provision negotiated by the Pool so it can sell tenofovir to a larger number of countries and without paying royalties. The Pool negotiated for its licences with Gilead to be “unbundled” – this means a generic manufacturer can elect to uptake licences on a product-by-product basis. Aurobindo chose to take licences covering emtricitabine, cobicistat, elvitegravir, and the Quad and not to take a licence on tenofovir, on which there is currently no product patent in India. This means that Aurobindo should be able to sell tenofovir to a larger number of countries than it was able to sell to before.
- 11 October 2011 press release
- Fully executed sublicence agreement, with TDF termination notice [pdf]
MedChem
Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of TDF, FTC, COBI, and EVG].
In July 2011, MedChem became the MPP’s first generic company sublicensee. MedChem is a new player in the HIV field. Attracting generic producers will help increase production capacity, which is needed to meet treatment goals.